• 보건행정학회지
• /
• 제27권3호
• /
• pp.247-255
• /
• 2017

Background: South Korea has experienced problems with excessive pharmaceutical expenditures. In 2010, the South Korean government introduced an outpatient prescription incentive program to effectively manage pharmaceutical expenditures. Therefore, we examined the relationship between the outpatient prescription incentive program and pharmaceutical expenditures. Methods: We used data from the Korean National Health Insurance claims database, which included medical claims filed for 22,732 clinics from 2011-2014 to evaluate associated pharmaceutical expenditures. We performed multiple regression analysis and Poisson regression analysis using generalized estimating equation models to examine the associations between outpatient prescription incentives and the outcome variables. Results: The data used in this study consisted of 123,392 cases from 22,372 clinics (average 5.4 periods follow-up). Clinics that had received outpatient prescription incentives in the last period had better cost saving and Outpatient Prescribing Costliness Index (OPCI) (received: proportion of cost saving, ${\beta}=6.8179$; p-value < 0.0001; OPCI, ${\beta}=-0.0227$; p-value < 0.0001; reference = non-received). Moreover, these clinics had higher risk in the provision of outpatient prescription incentive (relative risk, 2.772; 95% confidence interval, 2.720 to 2.824). The associations were higher in clinics that had separate prescribing and dispensing programs, or had professional staff. Conclusion: The introduction of an outpatient prescription incentive program for clinics effectively managed problems with rapid increases of pharmaceutical expenditures in South Korea. However, the pharmaceutical expenditures still increased in spite of the positive impact of the outpatient prescription incentive program. Therefore, healthcare professionals and health policy makers should develop more effective alternatives (i.e., for clinics without separate prescribing and dispensing programs) based on our results.

• Archives of Pharmacal Research
• /
• 제13권3호
• /
• pp.282-284
• /
• 1990

By saponification and extraction of corn oil foots abandoned as waste during oil refining, a mixture of phytosterols was obtained, and its major components were determined as .betha.-sitosterol, campesterol and stigmasterol by gas chromatographic analysis. The mixture is very cheap and regarded as an excellent substrate for direct fermentation of C-17 keto steroid intermediate for various steroid pharmaceuticals.

• Archives of Pharmacal Research
• /
• 제3권1호
• /
• pp.17-21
• /
• 1980

A sensitive spectrophotofluorometric method was developed for the analysis of 2[[3-(trifluoromethyl)phenyl]amino]-3-phridine carboxylic acid (I) in urine. The method is based on the fluoroscence behavior of the I-aluminum complex in absolute ethanol. This fluorophore has activation and emission wavelengths of 355 and 450 nm, respectively. Optimum conditions for the reaction were investigated. The fluorescence was linear in the range of 0.25 3.0 ug of I/ml. Replicate studies of spiked urine samples, each containing 2.5 ug of I/ml showed good precision with a relative standard deviation of 0.019. Overall recovery percent from five spiked urine samples was 99.4 $\pm$1.32%.

• Archives of Pharmacal Research
• /
• 제29권11호
• /
• pp.942-945
• /
• 2006

A novel quinone derivative, Griseusin C (1), along with a known quinone, Naphthoquinone C (2), was isolated from the lyophilized culture broth of the marine-derived fungus Penicillium sp. The structures were elucidated on the basis of extensive 1D-and 2D-NMR, as well as HRESIMS, spectroscopic analysis. The relative stereochemistries of the compounds were assessed by NOESY analysis.

• 한국산학기술학회논문지
• /
• 제14권11호
• /
• pp.5809-5818
• /
• 2013

본 논문에서는 '파이프라인 건전도(Pipeline Soundness)와 특허유효성(Patent Validity)개념을 적용하여 제약기업이 적합한 기술 아웃소싱 대상기업을 선정하기 위한 기술 포트폴리오 방법을 제시하고자 한다. 또한 이를 최근 발표한 Amgen의 Onyx Pharmaceuticals 인수사례에 적용하여 개발된 포트폴리오 분석방법의 실제 적용 가능성을 검토하고 사례기업의 기술아웃소싱 타당성을 분석하기로 한다. 본 연구를 통해 제시된 기술포트폴리오의 사례 적용 분석 결과 Amgen은 주력분야인 Cancer 분야의 특허유효성 개선이 시급한 것으로 분석되었으며 Onyx Pharmaceuticals의 인수를 통해 Cancer 분야의 기술포트폴리오를 안정적인 영역에 도달시킬 것으로 기대된다. Amgen의 실제 Onyx Pharmaceuticals 인수 이유 또한 Cancer 분야의 파이프라인 강화와 의약품 도입이라는 점을 고려할 때 새롭게 개발된 기술포트폴리오 분석방법이 실제사례에 잘 적용됨을 알 수 있었으며, 본 연구를 통해 개발된 기술포트폴리오 분석 방법이 제약기업의 기술현황 파악 및 인수대상기업 선정을 위한 도구로 충분히 활용 가능할 수 있을 것으로 판단된다.

• International Journal of Contents
• /
• 제12권4호
• /
• pp.76-82
• /
• 2016

This study aims to evaluate the effectiveness of the dual-punishment system by analysis of the financial performance of pharmaceutical companies before and after introduction of the dual-punishment system. This study analyzed the business performance of 136 pharmaceutical companies from 2009 to 2011. The results from paired t-tests found that sales, operating cost, and EBITDA showed significant differences in performance, and, according to the variance analysis, the five groups obtained through a hierarchical cluster analysis differed from each other in sales, operating cost, EBITDA, and research and development cost. Differences in financial performance among the groups seem to be related to the strategy for response to the regulation. The introduction of the dual-punishment system is generally acknowledged to have had positive effects on the pharmaceutical industry. However, some companies appear to be continuing kickback practices.

• Journal of Ginseng Research
• /
• 제48권4호
• /
• pp.395-404
• /
• 2024

Background: Ginsenoside Rg₁ (Rg₁) is one of the main active components in Chinese medicines, Panax ginseng and Panax notoginseng. Research has shown that Rg₁ has a protective effect on the cardiovascular system, including anti-myocardial ischemia-reperfusion injury, anti-apoptosis, and promotion of myocardial angiogenesis, suggesting it a potential cardiovascular agent. However, the protective mechanism involved is still not fully understood. Methods: Based on network pharmacology, ligand-based protein docking, proteomics, Western blot, protein recombination and spectroscopic analysis (UV-Vis and fluorescence spectra) techniques, potential targets and pathways for Rg₁ against myocardial ischemia (MI) were screened and explored. Results: An important target set containing 19 proteins was constructed. Two target proteins with more favorable binding activity for Rg₁ against MI were further identified by molecular docking, including mitogen-activated protein kinase 1 (MAPK1) and adenosine kinase (ADK). Meanwhile, Rg₁ intervention on H9c2 cells injured by H₂O₂ showed an inhibitory oxidative phosphorylation (OXPHOS) pathway. The inhibition of Rg₁ on MAPK1 and OXPHOS pathway was confirmed by Western blot assay. By protein recombination and spectroscopic analysis, the binding reaction between ADK and Rg₁ was also evaluated. Conclusion: Rg₁ can effectively alleviate cardiomyocytes oxidative stress injury via targeting MAPK1 and ADK, and inhibiting oxidative phosphorylation (OXPHOS) pathway. The present study provides scientific basis for the clinical application of the natural active ingredient, Rg₁, and also gives rise to a methodological reference to the searching of action targets and pathways of other natural active ingredients.

• 약학회지
• /
• 제54권2호
• /
• pp.142-149
• /
• 2010

Development of alternative testing methods for the replacement of hazardous reagents with less hazardous ones is strongly enforced because exposure of human and environment to hazardous reagents are restricted and hazardous reagents are gradually prohibited from using in various testing methods. Thus, in this study, we developed 8 monographs from the Korean Pharmaceutical Codex by substituting the use of the hazardous reagents including ICH class 1 such as benzene, chloroform and dioxane to the use of less toxic ones like ICH class 2 or 3 reagents. We also improved their qualification and quantification performance. Among 8 monographs, the 6 newly developed TLC methods for the identification of nifedipine, oxolamine citrate, ketoprofen lysinate, chlorquinaldol, retinol acetate, and riboflavin showed a clear spot of corresponding material without any interference in spite of the replacement with ICH class 2 or 3 reagents. For the quantification of domperidone and trimebutine, HPLC methods were developed for the substitution of UV/VIS spectrometry and titrimetry, respectively. These HPLC methods were validated for the linearity, recovery, reproducibility, and inter-laboratory variations. In conclusion, the newly developed methods could be expected to become valuable tools for revising the Korean Pharmaceutical Codex.

• 한국콘텐츠학회논문지
• /
• 제21권11호
• /
• pp.543-552
• /
• 2021

마케팅-영업-인터페이스(MSI) 능력은 영업사원들이 시장에서의 지식과 경험을 보다 효과적으로 조직 내부 자원들과 소통하는 능력으로서 영업성과에 긍정적인 영향을 주는 것으로 알려져 있다. 본 연구는 제약회사 영업사원의 마케팅-영업-인터페이스(MSI) 능력이 직무만족도를 통해 영업성과에 영향을 미치는 매개효과를 분석하였다. 전국 제약회사 5곳의 영업사원을 대상으로 2021년 4월 15일부터 4월 23일까지 설문조사를 실시하였으며, 총 257부를 최종 분석에 사용하였다. 분석 결과 영업사원이 지각하는 MSI능력은 직무만족도 및 영업성과에 통계적으로 유의한 정(+)의 영향을 보였다. 또한 제약회사 영업사원이 지각하는 MSI능력은 직무만족도를 매개하여 영업성과에 통계적으로 유의한 정(+)의 영향을 보였다. 분석결과는 제약회사 영업사원의 영업성과 향상을 위해 MSI능력과 직무만족도의 중요성을 시사하며, 직무만족도의 매개효과에 주목하여 영업사원 관리와 관련된 방안 마련이 필요함을 보여준다.

• 품질경영학회지
• /
• 제50권3호
• /
• pp.373-386
• /
• 2022

Purpose: This study proposes the application of Six Sigma management innovation method for more systematically enhanced execution of Quality by Design (QbD) activities. QbD requires a deeper understanding of the product and process at the design and development stage of the drug, and it is very important to ensure that no fault is fundamentally generated through thorough process control. Methods: Analyzing the background and specific procedures of quality improvement based on the drug design basis, and analyzing the key contents of each step, we have differentated and common points from the 6 Sigma methodology. We propose a new model of Six Sigma management innovation method suitable for pharmaceutical industry. Results: Regulatory agencies are demanding results from statistical analysis as a scientific basis in developing medicines to treat human life through quality improvement activities based on drug design. By utilizing the education system to improve the statistical analysis capacity in the Six Sigma activities and operating the 6 Sigma Belt system in conjunction, it helped systematically strengthen the execution power of quality improvement activities based on pharmaceutical design based on the members of the pharmaceutical industry. Conclusion: By using QbD Six Sigma, which combines quality enhancement based on pharmaceutical design basis and Six Sigma methodology suitable for pharmaceutical industry, it is possible to obtain satisfactory results both by pharmaceutical companies and regulators by using appropriate statistical analysis methods for preparing scientific evidence data required by regulatory.